Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.34 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.34 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.34 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713305 | 0.81 | ADRB2 (0.39) | CACNA1BSLC6A4KCNH2MAPK14ADRB2 | |
| SCHEMBL9901279 | 0.80 | FAAH (0.36) | LMNAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL875696 | 0.80 | LTA4H (0.50) | LMNAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL4373280 | 0.80 | ST14 (0.52) | LOXL2 | |
| SCHEMBL19773456 | 0.78 | VNN1 (0.36) | ADRB2LOXL2MAPT | |
| SCHEMBL1713166 | 0.78 | ADRB2 (0.37) | CACNA1BADRB2LMNALOXL2TP53 | |
| Hydrochloric Acid SCHEMBL1713787 | 0.78 | MAOB (0.50) | LOXL2 | |
| SCHEMBL9103247 | 0.77 | FAAH (0.42) | PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL1713662 | 0.76 | ACACB (0.45) | HTR2ASLC6A4KCNH2MAPK14ADRB2 | |
| SCHEMBL31137266 | 0.74 | CARM1 (0.48) | CACNA1BKCNH2LMNALOXL2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232101-A1 | Novel Compounds | CHAPMAN DAVID (SE) | 2012-09-13 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| EP-2097406-B1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2097406-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | Astra Zeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008065393-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221139-A1 | Novel Compounds | MMP9, MMP2, MMP1 | CACNA1B 3077/4885HTR2A 1776/4885SLC6A4 3452/4885 |
| US-20120232101-A1 | Novel Compounds | MMP9, MMP2, MMP1 | CACNA1B 3077/4885HTR2A 1776/4885SLC6A4 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.